Roche raised hopes this year that it had a future blockbuster drug on its hands after early trial results of the Swiss pharmaceutical group’s new obesity treatments showed rapid weight loss among recipients.
But revelations earlier this week of high rates of vomiting and other side effects among those who took strong doses of the drugs have unsettled investors and highlighted the challenges facing businesses that want to enter the lucrative new market for “GLP-1” drugs.
The company’s shares dropped 4 per cent on Monday after it revealed that three-quarters of patients on the highest dose of its CT-388 injection had suffered from vomiting. They fell another 5 per cent on Thursday after similar data for its oral weight-loss pill.
您已阅读12%（736字），剩余88%（5369字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。